Research
Hormonal
Sclerostin levels are elevated in individuals with Type 2 Diabetes and insulin resistance, and blocking sclerostin signaling improves insulin sensitivity in animal models.
High levels of sclerostin are linked to insulin resistance. While drugs targeting sclerostin (like romosozumab) exist for osteoporosis, their metabolic benefits are still being studied. For now, exercise and weight management remain the best ways to improve insulin sensitivity.
ModerateSupportsMEDIUM confidence
In a prospective cohort study (n = 1778), sclerostin levels were associated with fasting insulin levels and HOMA-IR... mice deficient in sclerostin (Sost-/-) have higher bone mass and lower visceral and subcutaneous fat mass, as well as improved insulin sensitivity
Why this rating
Strong association in humans and clear mechanistic benefit in knockout mice, but clinical translation is not yet established.
Source
The role of bone in energy metabolism: A focus on osteocalcin
Cassandra Smith et al. · Bone · 2024
DOI 10.1016/j.bone.2024.117238
narrative_reviewCited 21×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Exogenous administration of undercarboxylated osteocalcin (ucOC) improves whole-body and skeletal muscle glucose metabolism and insulin sensitivity in animal models, though human evidence remains discordant.Moderate
- Exercise increases circulating undercarboxylated osteocalcin (ucOC) levels, which is associated with increased whole-body insulin sensitivity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →